Clinical Trial Update: This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating empagliflozin in chronic heart failure with reduced ejection fraction, assessing 6-minute walk distance and HF symptoms; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2020-10-22